KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Evolent Health (EVH) over the last 11 years, with Q3 2025 value amounting to $9.0 million.

  • Evolent Health's Capital Expenditures rose 4250.28% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.5 million, marking a year-over-year increase of 3099.14%. This contributed to the annual value of $24.9 million for FY2024, which is 1340.06% down from last year.
  • According to the latest figures from Q3 2025, Evolent Health's Capital Expenditures is $9.0 million, which was up 4250.28% from $8.8 million recorded in Q2 2025.
  • Over the past 5 years, Evolent Health's Capital Expenditures peaked at $10.7 million during Q4 2022, and registered a low of $5.3 million during Q1 2024.
  • Over the past 5 years, Evolent Health's median Capital Expenditures value was $7.1 million (recorded in 2024), while the average stood at $7.5 million.
  • In the last 5 years, Evolent Health's Capital Expenditures tumbled by 4459.47% in 2021 and then surged by 6578.71% in 2022.
  • Quarter analysis of 5 years shows Evolent Health's Capital Expenditures stood at $7.2 million in 2021, then surged by 48.3% to $10.7 million in 2022, then tumbled by 43.67% to $6.1 million in 2023, then increased by 1.64% to $6.2 million in 2024, then surged by 45.7% to $9.0 million in 2025.
  • Its Capital Expenditures stands at $9.0 million for Q3 2025, versus $8.8 million for Q2 2025 and $8.6 million for Q1 2025.